Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU)

Kewaunee Scientific FY2026 revenue rises to $282.0 million; EBITDA reaches $22.4 million

Positive Impact 3 of 5 earnings Written later

At its virtual annual shareholder meeting, Kewaunee Scientific reported fiscal 2026 (ended April 30, 2026) revenue of $282.0 million, EBITDA of $22.4 million and net earnings of $9.6 million. Year-end backlog fell to $165.9 million from $214.6 million, which the company attributed mainly to completing several large international projects.

Key points

  • Fiscal 2026 revenue was $282.0 million; EBITDA was $22.4 million, up from $21.6 million in fiscal 2025.
  • Lab Products Group sales rose 19.8% to $214.9 million; International segment sales rose 9.9% to $67.1 million.
  • Consolidated backlog was $165.9 million at April 30, 2026, versus $214.6 million a year earlier.
  • Long-term debt was reduced by about $20 million, and debt-to-equity improved to 0.61-to-1.0 from 0.99-to-1.0.

The filing

CompanyKEWAUNEE SCIENTIFIC CORP /DE/ (KEQU)
Form8-K, current report
Filed with the SECAug 26, 2026, 6:10 AM ET
Accession number0000055529-26-000025

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.